SCYNEXIS INC cotiza a 3.99 USD y tiene una capitalización bursátil de $40M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recur…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $0.63 | $-3.36 | $2.00 |
| Estimado | $-0.72 | $-0.51 | $-0.99 | $1.01 |
| Sorpresa | — | +223.5% | -239.4% | +98.0% |
| Métrica | SCYX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -78.0% | -38.6% | -39.4% |
| Net Margin | -41.8% | -33.6% | -8.2% |
| FCF Margin | — | -13.9% | — |
| ROE | -17.4% | -40.4% | +23.0% |
| ROA | -14.6% | -32.0% | +17.4% |
| Current Ratio | 7.04 | 2.84 | +4.20 |
| Debt / Equity | — | 0.28 | — |